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This dissertation is mainly composed by two parts, the first part demonstrated a 
laboratory method to isolation the DNA of Mycobacterium tuberculosis (TB) based 
on  the  magnet  glass  particles  (MGP),  and  further  optimization  has  been  performed.  
With these works, we have authenticated the availability of the method we developed. 
The second part fully reviewed the PCR-melt curve based mutation genotyping kit 
through genotyping clinical samples, and further introduced the advantage and 
disadvantage in clinical application.  
The TB possesses thick cell wall, and therefore, difficult to break. Meanwhile, the 
sputum of TB patients contains great deal of secretion and mucoprotein, these factors 
would compromise the DNA isolation of TB, and consequently impose negative effect 
on the rapid diagnosis.  
We have established an isolation method by using MGP, first heat and lysis were 
employed to break cell wall, and wash off the other residue component in sputum by 
using adsorption induced by MGP, and finally acquired the nucleic acid with high 
quality. We further optimized the heat time, volume and time of lysis and established 
an improved isolation protocol. We investigate the sensitivity of this method by 
simulating the sputum with TB, the results indicated this method is capable of 
performing PCR with a bacteria concentration of 200CFU/mL. This isolation method 
has been performed in 140 clinical samples, and PCR amplification was successfully 
conducted among 85 positive samples of them with a sensitivity of 100%. However, 
we have also isolated TB DNA among negative samples, it may due to the limitation 
of acid-fast staining method and the specificity of PCR.  
We have performed drug sensitivity test and four sets of PCR melt curve test by 
using  genotyping  kit  (RFP,  INH,  SM  and  EMB).  The  results  showed  that  the  
sensitivity  of  RFP  genotyping  kit  reached  100%,  and  has  97.8%  specificity.  The  
















The sensitivity and specificity for SM genotyping kit were 85.3% and 98.2%, 
respectively. The sensitivity and specificity for EMB genotyping kit were 90.9% and 
97.9%, respectively. These results indicated the specificity of all genotyping kit was 
satisfactory, and among them, RFP genotyping kit maintains highest sensitivity. In 
summary,  the  sensitivity  and  specificity  of  all  kits  was  satisfactory  and  has  solid  
performance in clinical application.  
   We further investigate the genotyping time, genotyping level, kit stability, 
contamination, different PCR instrument, and result determination of 6 genotyping 
kits through genotyping of 605 clinical samples. By using our method, the DNA 
isolation and genotyping of mutations relating 6 antibiotics can be finished from 2-3 
days. Comparing with the traditional drug sensitivity test, we have saved considerable 
time, and which is the most important advantage our method can provide. We have 
investigated the genotyping threshold of all 6 kits, and the differences detected, and 
among them, quinolones genotyping kit has lowest detecting threshold. And we 
evaluated the performance of kits in 10days, 1month, 2months and 3months, the 
results indicated there was no significant change in kit performance, while the 
performance  would  reduce  slightly  after  3months.  As  for  the  contamination,  only  3  
events occurred during whole procedure, and in contrast, 15 events occurred in 
traditional drug sensitivity test. We can assume that the kits possess high performance 
and capability, however, the improvement in result determination must be performed, 
currently it may require more technique and skill for laboratory personnel.  
Combined results from all evaluations, we can concluded that melt curve PCR is 
a fast and reliable genotyping method, and it possesses both high sensitivity and 
specificity, moreover, it can avoid laboratory contamination, therefore, it has solid 
performance and positive prospect in clinical application. 
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2000 800-1000 [6] 300
 
2010 [7] 2009 940
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1-1.  2012 [8] 
Figure 1-1.  Estimated TB incidence rates 2012 
1.2.2  
1-1:  2010 [9] 
Table 1-1:  The national tuberculosis epidemic situation in 2010 




  499 459/10
  72 66/10
  129 119/10
 
  5.4 4.1/10
  5.2 3.9/10
 
  / TB/HIV 2
  MDR-TB 10
[10, 11]
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